Robert Coleman, MD, FACOG, FACS
Although the prevalence of ovarian cancer has increased in the last 3 years, incidence and death rates have decreased as a result of novel therapies, including angiogenesis inhibitors, immunotherapies, PARP inhibitors, and refined patient classification schemes, explained Robert L. Coleman, MD, FACOG, FACS.
State of the Science Summit™ on Ovarian Cancer, Coleman discussed the evolution of treatment for patients with ovarian cancer, the therapies with the most potential, and the importance of classification schemes in directing treatment in recurrent disease.
OncLive: How has the field of recurrent ovarian cancer evolved in recent years?
: One of the things that I’ve mentioned many times, but [that] is becoming more apparent, is that the prevalence of ovarian cancer is increasing. A lot of that is due to the fact that women who have recurred are being treated multiple times with therapies that are extending the time of progression independently. Very few trials we have now can show an overall survival (OS) change in patients who enter the trial at one point as a cohort. We do see a lot of progression-free survival (PFS) advancements. On an individual level, when that is what a patient experiences, the life expectancy of that patient increases.
... to read the full story